These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Use of cell cultures in vaccine production: primary cell cultures. Smith KO J Am Vet Med Assoc; 1970 Jun; 156(12):1787-90. PubMed ID: 5463597 [No Abstract] [Full Text] [Related]
24. Viral flora of tissue sources and tissue and medium antigens in vaccines--general comments. Jensen KE Natl Cancer Inst Monogr; 1968 Dec; 29():207-8. PubMed ID: 5720793 [No Abstract] [Full Text] [Related]
25. The need for a standardised cell substrate for virus vaccine production. Perkins FT Ann Ist Super Sanita; 1969; 5(1):82-9. PubMed ID: 5382315 [No Abstract] [Full Text] [Related]
27. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Monath TP; Myers GA; Beck RA; Knauber M; Scappaticci K; Pullano T; Archambault WT; Catalan J; Miller C; Zhang ZX; Shin S; Pugachev K; Draper K; Levenbook IS; Guirakhoo F Biologicals; 2005 Sep; 33(3):131-44. PubMed ID: 15975826 [TBL] [Abstract][Full Text] [Related]
28. A nonhuman primate model for preclinical testing of new tuberculosis vaccines. McMurray DN Clin Infect Dis; 2000 Jun; 30 Suppl 3():S210-2. PubMed ID: 10875785 [TBL] [Abstract][Full Text] [Related]
29. U.S. laws, regulations, and policies important to managers of nonhuman primate colonies. Johnson DK; Morin ML J Med Primatol; 1983; 12(5):223-38. PubMed ID: 6680147 [TBL] [Abstract][Full Text] [Related]
30. [Virus transmission in the tropical environment, the socio-ecology of primates and the balance of ecosystems]. Galat G; Galat-Luong A Sante; 1997; 7(2):81-7. PubMed ID: 9273125 [TBL] [Abstract][Full Text] [Related]
31. Use of PCR for extranous agent testing in avian vaccines. Ottiger HP Dev Biol (Basel); 2002; 111():23-6. PubMed ID: 12678221 [TBL] [Abstract][Full Text] [Related]
32. Cell cultures for virus vaccine production. General conclusions from the conference. Merchant DJ Natl Cancer Inst Monogr; 1968 Dec; 29():583-4. PubMed ID: 5720811 [No Abstract] [Full Text] [Related]
33. Production of human virus vaccines in primary mammalian cells. Stones PB Lab Pract; 1970 Jan; 19(1):40-1 passim. PubMed ID: 4984598 [No Abstract] [Full Text] [Related]
34. Regulatory constraints as seen from the pharmaceutical industry. Galligani G; David-Andersen I; Fossum B Dev Biol (Basel); 2005; 121():235-41. PubMed ID: 15962486 [TBL] [Abstract][Full Text] [Related]
35. Are primate models of neuropsychiatric disorders useful to the pharmaceutical industry? Howard JL; Pollard GT Prog Clin Biol Res; 1983; 131():307-12. PubMed ID: 6417668 [No Abstract] [Full Text] [Related]
36. Comments on technology of production--continuous cell lines. Daniels WF Natl Cancer Inst Monogr; 1968 Dec; 29():71-2. PubMed ID: 5720813 [No Abstract] [Full Text] [Related]
37. Large-scale production of indefinitely propagated cell lines. Cooper PD Natl Cancer Inst Monogr; 1968 Dec; 29():63-7. PubMed ID: 5720812 [No Abstract] [Full Text] [Related]
38. Experience with vaccines--summary. Koprowski H; Jackson GG Natl Cancer Inst Monogr; 1968 Dec; 29():565-6. PubMed ID: 5720809 [No Abstract] [Full Text] [Related]
39. Product quality control testing for the oral polio vaccine. Brock B; Kelleher L; Zlotnick B Dev Biol Stand; 1998; 94():217-9. PubMed ID: 9776242 [TBL] [Abstract][Full Text] [Related]
40. Technology of production of primary and diploid cell cultures. Brackett RG Natl Cancer Inst Monogr; 1968 Dec; 29():33-4. PubMed ID: 5720801 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]